Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | NSD2 | O96028 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.50 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycerin SCHEMBL6953616 | 0.89 | POLB (0.80) | POLBKMT2ALMNAGAAALDH1A1 | |
| SCHEMBL8894072 | 0.83 | POLB (0.71) | POLBKMT2ALMNAGAAALDH1A1 | |
| SCHEMBL6280961 | 0.82 | POLB (0.68) | POLBKMT2AMEN1NPC1 | |
| SCHEMBL28496721 | 0.81 | POLB (0.68) | POLBKMT2ALMNAGAAALDH1A1 | |
| SCHEMBL18107018 | 0.80 | POLB (0.63) | POLBKMT2ALMNAGAAALDH1A1 | |
| SCHEMBL6953048 | 0.79 | POLB (0.62) | POLBKMT2ALMNAGAAALDH1A1 | |
| SCHEMBL10188488 | 0.78 | POLB (0.64) | POLBKMT2ALMNAGAAALDH1A1 | |
| SCHEMBL16346255 | 0.78 | POLB (0.63) | POLBKMT2ALMNAGAAALDH1A1 | |
| SCHEMBL2454041 | 0.78 | POLB (0.63) | POLBKMT2ALMNAGAAALDH1A1 | |
| SCHEMBL21259220 | 0.77 | POLB (0.62) | POLBKMT2ALMNAGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116621775-A | 2-amino-5-hydroxytetrahydronaphthalene derivative containing hydroxypyridone side chain, preparation and application thereof | 浙江大学 | 2023-08-22 | — | — | CN | claimed |
| CN-116478130-B | N-hydroxyquinoline carboxamide compounds and uses thereof | 深圳默元生物科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20240279238-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2024-08-22 | — | — | US | disclosed |
| CN-116621775-A | 2-amino-5-hydroxytetrahydronaphthalene derivative containing hydroxypyridone side chain, preparation and application thereof | 浙江大学 | 2023-08-22 | — | — | CN | disclosed |
| WO-2023138674-A1 | N-HYDROXYQUINOLINE CARBOXAMIDE COMPOUND AND USE THEREOF | 默达药物（香港）有限公司 | 2023-07-27 | — | — | WO | disclosed |
| CN-116478130-A | N-hydroxyquinoline carboxamide compounds and uses thereof | 深圳默元生物科技有限公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-3045206-B2 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-3045206-B2 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20220213121-A1 | SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2022-07-07 | — | — | US | disclosed |
| US-11267823-B2 | Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1′,2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having HIV integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2022-03-08 | — | — | US | disclosed |
| EP-1021457-B1 | METHOD FOR THE SITE SPECIFIC SYNTHESIS OF NOVEL 3-HYDROXYPYRIDIN-4(1H)-ONES DERIVATIVES FROM AMINOITOLS, PRODUCTS OBTAINED BY THIS METHOD AND THEIR APPLICATIONS | ISTITUTO BIOCHIMICO PAVESE PHA (IT) | 2003-04-09 | — | — | EP | disclosed |
| EP-1134214-A1 | PICOLINAMIDE DERIVATIVES AND PEST CONTROLLERS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2001-09-19 | — | — | EP | disclosed |
| WO-2001017497-A1 | DEPIGMENTING COMPOSITIONS | GHISALBERTI CARLO (BR) | 2001-03-15 | — | — | WO | disclosed |
| US-6177409-B1 | 2-(ALKYL OR HALOALKYL)-3-HYDROXY PYRAN-4-ONE IS HYDROXYL-PROTECTED, AND REACTED WITH AN AMINO ITOL TO SUBSTITUTED THE INTRACYCLIC OXYGEN OF PYRANONE WITH THE AMINE OF THE AMINO ITOL; IRON(III) CHELATORS FOR BLOOD DISORDERS | INSTITUTO BIOCHIMICO PAVESE PHARMA S.P.A. (IT) | 2001-01-23 | — | — | US | disclosed |
| US-5399566-A | Hypotensive | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1995-03-21 | — | — | US | disclosed |
| WO-1992013841-A1 | COMPLEXING AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1992-08-20 | — | — | WO | disclosed |
| EP-0498380-A1 | Complexing agents | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1992-08-12 | — | — | EP | disclosed |
| EP-0487745-A1 | PYRIDINE DERIVATIVE WITH ANGIOTENSIN II ANTAGONISM | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1992-06-03 | — | — | EP | disclosed |
| US-5112968-A | Monobactam hydrazide derivatives | E. R. SQUIBB & SONS, INC. (US) | 1992-05-12 | — | — | US | disclosed |
| EP-0336369-A1 | 3-Acylamino-1-[[[(substituted sulfonyl)amino]carbonyl]amino]2-azetidinones | E.R. Squibb & Sons, Inc. (US) | 1989-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213121-A1 | SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY | TYMP, TYMS, POLA1 | POLB 7/4885KMT2A 2434/4885LMNA 2002/4885 |
| US-11267823-B2 | Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1′,2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having HIV integrase inhibitory activity | TYMP, TYMS, POLA1 | POLB 6/4885KMT2A 2435/4885LMNA 1966/4885 |
| US-20240279238-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | TYMP, CDKN1A, POLL | POLB 15/4885KMT2A 617/4885LMNA 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.